Search 

Mesa Verde Venture Partners is a Venture Capital company founded in 2006. The firm is currently making investments out of its 2nd fund that had its first close in 2013. The firm makes primarily equity investment into seed and early stage rounds ranging from $500,000 to $1 million initially and up to $1.5 million over the lifetime of the investment. The firm is focused on companies located in the Southwestern United States although they are open to review companies from throughout the US. The firm could make as many as 3 new investments over the next 6-9 months.

Mid Atlantic Bio Angels (MABA) founded in 212 is an angel investor group based in the New York City area which focuses exclusively on new and emerging life science companies. The group places no geographical restrictions or requirements for presenting companies as long as meaningful and effective post-investment monitoring of these companies can be achieved, MABA has considered opportunities in Europe and Israel as well as across the USA and Canada. Since the members are investing their own capital the investment size is highly flexible and will depend on the financial needs of the company. The capital structure is typically in preferred stocks or convertible notes in qualified cases. The group prefers to invest in companies with valuations of less than $5M. As MABA prefers opportunities that can be entirely angel-financed MABA generally requires that companies can achieve exit with $15 million capital or under (generally after raising a Series B round but no further rounds).

The Office of Translational Alliances and Coordination (OTAC) at the National Heart, Lung, and Blood Institute supports the development of innovative biomedical products to address unmet medical needs in the heart, lung, blood and sleep fields.  OTAC is home to the NHLBI's small business programs (SBIR and STTR) and the NIH Centers for Accelerated Innovations.

The NHLBI's SBIR and STTR programs comprise one of the largest sources of early-stage capital for U.S. small business, acting as engines of innovation for developing and commercializing novel technologies and products that aid in the prevention, diagnosis, and treatment of heart, lung, blood, and sleep diseases and disorders. The NHLBI provides grant and contract funding opportunities and resources to support small businesses performing research and development on technologies related to the mission of NHLBI. With an annual budget of $85M, the NHLBI funds about 200 companies each year through the Institute's small business programs.

The NIH Centers for Accelerated Innovations accelerate translation of scientific discovery into commercial products that improve health for patients. This unique public-private partnership is changing the way discoveries with scientific and commercial potential are identified and developed.

Comprising 10 investment professionals, Omnes Capital’s venture capital team acquires minority stakes in young companies with high growth potential. Its main areas of interest are financing innovative business ventures in the information technology and life sciences sectors (drug development, diagnostics, medical devices, bioproduction).

For 12 years, Omnes Capital has managed FCPI mutual funds (French regulated mutual funds investing in innovative companies).

Plug and Play Ventures (a successor fund to Amidzad Partners) is a private/family investment vehicle based in Silicon Valley, CA. The fund is a structured organization for making angel investments in pre-seed or seed rounds. Investments are in the form of equity; in the next 6 months Plug and Play Ventures expects to make about 5-10 seed investments of $50,000-100,000 and an additional 40 pre-seed investments of $25,000, and is hoping to increase their allocations in the healthcare sector. Plug and Play also provides a three-month accelerator program. The firm will consider investing in companies worldwide.

Plug and Play Ventures is interested in investing in medical technology, and invests in subsectors in which the firm can apply expertise; typically this means products that have a significant software component. Healthcare IT, biosensors, wearables and health monitoring devices are of interest. While the firm is open to investing in any indication, Plug and Play is particularly interested in diabetes & blood glucose monitoring, personal fitness, and mental/behavioral disorders. In the healthcare IT sector, Plug and Play Ventures is interested in both consumer applications and enterprise software, but is not interested in diagnostic software such as genomic, proteomic, or molecular diagnostic algorithms; however, optimization and data analysis software for hospitals and diagnostic laboratories is of interest.

Plug and Play Ventures (a successor fund to Amidzad Partners) is a private/family investment vehicle based in Silicon Valley, CA. The fund is a structured organization for making angel investments in pre-seed or seed rounds. Investments are in the form of equity; in the next 6 months Plug and Play Ventures expects to make about 5-10 seed investments of $50,000-100,000 and an additional 40 pre-seed investments of $25,000, and is hoping to increase their allocations in the healthcare sector. Plug and Play also provides a three-month accelerator program. The firm will consider investing in companies worldwide.  

Plug and Play Ventures is interested in investing in medical technology, and invests in subsectors in which the firm can apply expertise; typically this means products that have a significant software component. Healthcare IT, biosensors, wearables and health monitoring devices are of interest. While the firm is open to investing in any indication, Plug and Play is particularly interested in diabetes & blood glucose monitoring, personal fitness, and mental/behavioral disorders. In the healthcare IT sector, Plug and Play Ventures is interested in both consumer applications and enterprise software, but is not interested in diagnostic software such as genomic, proteomic, or molecular diagnostic algorithms; however, optimization and data analysis software for hospitals and diagnostic laboratories is of interest.